NCT06136949 The Theranostic Value of STARD3 in Colorectal Cancer: The STAR Study
| NCT ID | NCT06136949 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centro di Riferimento Oncologico - Aviano |
| Condition | Colorectal Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2023-05-22 |
| Primary Completion | 2032-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2023-05-22 with a primary completion date of 2032-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims at verifying the overexpression of STARD3 in both early and advanced CRC patients derived tissues, to identify the pathways underpinning tumorigenesis and cancer progression in which STARD3 is involved. Moreover its role as a dynamic biomarker of treatment response and its part in treatment sensitivity will be explored.
Eligibility Criteria
Inclusion Criteria: * Histologically confirmed diagnosis of colorectal cancer, independently from diagnosis stage. * Age ≥18 years. * Signed informed consent form. * Availability of tissue and blood samples stored at the Institutional Biobank for research purposes. Exclusion Criteria: * Patients for which the tumour biobanking process could compromise the diagnostic assessments. * Pregnancy or breast-feeding. * History of concomitant or previous malignancy in the previous 5 years, except for adequately treated cutaneous squamous cell carcinoma or surgically removed in situ cervical carcinoma.
Contact & Investigator
Vincenzo Canzonieri, MD,PhD
PRINCIPAL INVESTIGATOR
Centro di Riferimento Oncologico di Aviano (CRO) - IRCCS
Frequently Asked Questions
Who can join the NCT06136949 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Colorectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06136949 currently recruiting?
Yes, NCT06136949 is actively recruiting participants. Contact the research team at vcanzonieri@cro.it for enrollment information.
Where is the NCT06136949 trial being conducted?
This trial is being conducted at Aviano, Italy.
Who is sponsoring the NCT06136949 clinical trial?
NCT06136949 is sponsored by Centro di Riferimento Oncologico - Aviano. The principal investigator is Vincenzo Canzonieri, MD,PhD at Centro di Riferimento Oncologico di Aviano (CRO) - IRCCS. The trial plans to enroll 150 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.